Sage Mountain Advisors LLC Sells 838 Shares of Novo Nordisk A/S (NYSE:NVO)

Sage Mountain Advisors LLC reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 12.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,759 shares of the company’s stock after selling 838 shares during the quarter. Sage Mountain Advisors LLC’s holdings in Novo Nordisk A/S were worth $495,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Folketrygdfondet lifted its position in shares of Novo Nordisk A/S by 0.5% during the 4th quarter. Folketrygdfondet now owns 8,903,938 shares of the company’s stock valued at $765,917,000 after buying an additional 40,313 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $404,910,000. WCM Investment Management LLC lifted its holdings in Novo Nordisk A/S by 1.0% during the fourth quarter. WCM Investment Management LLC now owns 4,031,124 shares of the company’s stock valued at $345,588,000 after purchasing an additional 40,475 shares in the last quarter. Amundi boosted its position in shares of Novo Nordisk A/S by 26.4% in the fourth quarter. Amundi now owns 3,311,456 shares of the company’s stock worth $283,615,000 after purchasing an additional 692,567 shares during the period. Finally, Natixis Advisors LLC raised its position in shares of Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 1.0 %

Shares of NVO stock opened at $78.14 on Wednesday. The company has a market cap of $350.63 billion, a PE ratio of 23.75, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 1 year low of $73.28 and a 1 year high of $148.15. The stock’s 50 day simple moving average is $84.61 and its two-hundred day simple moving average is $104.04. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s payout ratio is currently 47.72%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.